James Scibetta joined Aquestive’s Board of Directors in 2017. He is currently CEO of Maverick Therapeutics, a development stage immune-oncology company. Prior to Maverick, Mr. Scibetta was President of Pacira Pharmaceuticals (Nasdaq: PCRX) where he oversaw commercial and medical support activities, and directed commercial manufacturing, tech transfer, and R&D. Mr. Scibetta served as Pacira’s Chief Financial Officer from 2008 through May 2016 where he led its 2011 IPO and subsequent debt and equity financings. Prior to that, he was an executive with Bioenvision Inc. (Nasdaq: BIVN), a commercial stage oncology company acquired by Genzyme, and Merrimack Pharmaceuticals, an oncology-focused systems biology company. Earlier in his career he spent over a decade in investment banking where he was responsible for sourcing and executing transactions for a broad base of public and private healthcare and life sciences companies. He serves as a Board director and chairman of the audit committee of Matinas BioPharma (NYSE: MTNB). Mr. Scibetta received his B.S. in Physics from Wake Forest University and his MBA from the University of Michigan.